On November 24, 2025, results from a clinical trial conducted by Ankara City Hospital Bilkent on the use of extracorporeal shock wave therapy (ESWT) for managing low back pain were officially made available. This trial, now marked as completed, sheds light on the application of ESWT in physical therapy for patients experiencing this common condition. Clinical, quality, and regulatory professionals may find the findings vital for understanding potential updates in therapeutic protocols and device regulation.
What is ESWT and its role?
ESWT, or extracorporeal shock wave therapy, is a non-invasive procedure using acoustic waves to deliver targeted energy to soft tissues, stimulating healing and reducing pain. Initially developed for lithotripsy, the technology has expanded into musculoskeletal applications, including low back pain—a condition that affects millions globally. Its mechanism aims to enhance localized blood circulation and cellular repair processes, providing a potential adjunct to traditional physical therapy techniques.
Study objectives and methodology
The clinical trial completed by Ankara City Hospital Bilkent explored the role of ESWT in managing low back pain within a physical therapy context. Using evidence-based principles, this study aimed to evaluate the efficacy, safety, and performance of the therapy. Participants underwent structured ESWT sessions as an intervention categorized under “Other” therapies. The structured approach ensures adherence to hospital protocols and regulatory safety standards, meeting criteria outlined by the ClinicalTrials.gov registry.
The trial’s completed status indicates robust data collection and analysis phases, offering insights for healthcare providers, device manufacturers, and policymakers in optimizing treatment pathways. However, further breakdown of results, particularly regarding specific outcomes or patient-reported improvements, is essential for interpreting the broader significance.
Clinical and regulatory implications
Healthcare professionals managing low back pain may consider ESWT as a complementary therapy, especially in cases where conventional physical therapy methods lack sufficient efficacy. The results may also influence device manufacturers aiming to expand market indications for ESWT systems, underlining the importance of regulatory compliance regarding performance verification and risk management.
Regulatory authorities, including those in Europe adhering to MDR Annex XIV, might factor findings into device classifications, ensuring intended purposes align with clinical trial outcomes. These frameworks provide assurance of device performance and patient safety, supporting the broader adoption of ESWT as a viable option.
Frequently Asked Questions
Q1: What is known about ESWT’s safety?
ESWT is widely recognized as safe for musculoskeletal applications when appropriately administered. Clinical settings ensure professional monitoring and adherence to guidelines.
Q2: Who might benefit most from ESWT?
Patients with chronic low back pain unresponsive to conventional therapies, or those seeking non-invasive options, may find ESWT promising.
Q3: Is ESWT widely available?
While availability varies geographically, many specialized clinics and physical therapy centers offer ESWT, supported by trained medical professionals.
Conclusion
The successful completion of this clinical trial emphasizes the possibilities of ESWT as a supplemental therapy for low back pain. Stakeholders across clinical, quality, and regulatory sectors should consider the findings for advancing care standards. Collaboration between regulatory bodies and healthcare institutions may further optimize ESWT’s integration into therapeutic protocols.
Disclaimer
This content is intended for healthcare and regulatory professionals. It is not legal or medical advice. Professionals should consult appropriate resources before making decisions based on trial findings.
Source and link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07245498?term=medical+device